CytomX Therapeutics Inc

NASDAQ:CTMX   4:00:00 PM EDT
1.64
-0.07 (-4.09%)
7:57:50 PM EDT: $1.68 +0.04 (+2.44%)
Earnings Announcements

CytomX Therapeutics Reports Q3 2022 Results

Published: 11/08/2022 22:49 GMT
CytomX Therapeutics Inc (CTMX) - Cytomx Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update.
Qtrly Total Revenue Was $16.9 Million Compared to $17.6 Million for Corresponding Period in 2021.
Qtrly Net Loss per Share $0.35.
Q3 Earnings per Share View $-0.31, Revenue View $18.2 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $18.68 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $14.19 Million
Next Quarter EPS Guidance is expected to be -$0.25

More details on our Analysts Page.